MarketPulse
L

$LLY

176 articles found
111 positive
14 negative
50 neutral
The Motley FoolThe Motley Fool··Emma Newbery

Markets Rally as Iran Tensions Ease, Oil Slides for Second Straight Day

U.S. stocks surge on fading geopolitical tensions and falling oil prices. S&P 500 rises 0.72% despite YTD losses.
MULLYDALCVXNKE+4earningssemiconductor stocks
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

AAVantgarde Bolsters Leadership with Adverum Veteran Philip Lao as SVP

AAVantgarde Bio names Philip Lao as SVP of Business Development. Lao previously led Adverum's sale to Eli Lilly, bringing pharma expertise from Novartis, Pfizer, and Takeda.
LLYstrategic partnershipsgene therapy
BenzingaBenzinga··Not Specified

Eli Lilly's Centessa Acquisition Validates Nxera's Drug Discovery Platform

Eli Lilly acquires Centessa Pharmaceuticals, which developed sleep-disorder treatments with Nxera Pharma. Nxera retains royalties, milestones, and equity stake.
LLYCNTAacquisitiondrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Eli Lilly Acquires Centessa Pharmaceuticals in Sleep-Wake Drug Push

Eli Lilly acquires Centessa Pharmaceuticals, developer of OX2R agonists for sleep disorders co-created with Nxera Pharma, which retains milestone payments and royalties.
LLYCNTAacquisitiondrug discovery
BenzingaBenzinga··Piero Cingari

Trump's Iran Peace Signals Spark Market Rally, But S&P 500 Still Headed for Worst Month Since 2022

S&P 500 surges 1.8% on Trump's Iran peace signals; Nasdaq 100 rises 2%. Despite rally, index down 6.2% monthly toward worst month since September 2022.
DELLNVDAMETAMSFTSNDK+8semiconductor stocksS&P 500
BenzingaBenzinga··Vandana Singh

Eli Lilly to Acquire Centessa for $6.3B, Bolstering Sleep Medicine Push

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B upfront plus $1.5B in contingent payments, gaining sleep disorder pipeline including cleminorexton candidate.
LLYCNTAacquisitionneuroscience
The Motley FoolThe Motley Fool··Emma Newbery

Oil Surge to 4-Year High Triggers Market Rotation as Tech Stumbles on Valuation Fears

Markets shift defensive as Brent crude hits $114 amid Iran tensions. Nasdaq falls 0.7% on AI concerns while energy stocks rally.
NVDAMETAMSFTSNDKMU+9inflationFederal Reserve
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bile Duct Cancer Market Eyes $3.89B by 2030 on Therapy Advances

Global bile duct cancer market projected to reach $3.89B by 2030 from $2.59B in 2025, driven by immunotherapy, AI diagnostics, and rising disease prevalence.
BMYCELGrABBVLLYAZN+1pharmaceutical innovationimmunotherapy
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's Comeback Play: GLP-1 Pivot and 6.2% Yield Appeal to Long-Term Investors

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.
PFELLYNVOdividend yieldGLP-1 drugs
The Motley FoolThe Motley Fool··Thomas Niel

Viking Therapeutics' VK2735 Could Reshape Weight Loss Market—If Phase 3 Succeeds

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.
PFELLYNVOVKTXclinical trialsVK2735
The Motley FoolThe Motley Fool··Sean Williams

Trillion-Dollar TSMC Faces Rare Institutional Exodus Amid Tariff Fears

Institutional investors cut TSMC holdings by 2.8% in Q4 2025, citing profit-taking, rebalancing, and Trump tariff concerns despite the chip giant's AI dominance.
WMTNVDALLYTSMBRK.A+2institutional investorsprofit-taking
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.
PFELLYNVOGLP-1 drugsZepbound
GlobeNewswire Inc.GlobeNewswire Inc.··Sk Pharmteco

SK Pharmteco Convenes Pharma Manufacturing Leaders for Innovation Summit

SK pharmteco hosts April 8 Cambridge symposium on advanced pharmaceutical manufacturing, featuring leaders from Gilead, Eli Lilly, Amgen, and Antheia discussing continuous production innovations.
AMGNLLYGILDCDMOsymposium
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sitryx to Showcase Autoimmune Pipeline at Four Major Biopharma Conferences in April

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.
LLYGSKoral therapyinvestor conference
BenzingaBenzinga··Vandana Singh

Novo Nordisk's Experimental Obesity Drug Shows Superior Results to Semaglutide

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.
LLYNVOweight losssemaglutide
The Motley FoolThe Motley Fool··Marc Guberti

Stay the Course: Why Long-Term Strategy Beats Panic in Market Downturns

Investors should maintain long-term perspective during volatile markets, avoid panic selling, and reassess risk tolerance through strategic cash reserves and diversified holdings rather than emotional decisions.
LLYmarket volatilityportfolio diversification
BenzingaBenzinga··Vandana Singh

Abivax Dismisses M&A Speculation, Plans Capital Raise Before Trial Readout

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.
LLYAZNABVXFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

Eli Lilly Phases Out Select European Insulin Products by 2027

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.
LLYweight lossEurope
BenzingaBenzinga··Vandana Singh

Eli Lilly Surges on China Expansion Despite Supreme Court Lawsuit Setback

Eli Lilly announces $3B China investment and Mounjaro reimbursement win, but faces multibillion-dollar lawsuit over Actos disclosures.
LLYAAPLTAKclass action lawsuitMounjaro
GlobeNewswire Inc.GlobeNewswire Inc.··Amphista Therapeutics

Amphista Therapeutics Showcases Next-Gen Cancer Degraders at AACR Meeting

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.
LLYNVScancer treatmentprotein degradation